Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

Medical Journal of Australia

Volumn 201, Issue 1, 2014, Pages 49-53

  Alexander, Marliese ^a   Mellor, James D ^a   McArthur, Grant ^a   Kee, Damien ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IPILIMUMAB; LACTATE DEHYDROGENASE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; CHILD; COLITIS; CUTANEOUS MELANOMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HEPATITIS; HISTOLOGY; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; INFANT; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MORBIDITY; MUCOSAL MELANOMA; MYASTHENIA GRAVIS; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; UVEA DISEASE; UVEA MELANOMA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHOCYTE COUNT; MELANOMA; MUCOUS MEMBRANE; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 84904507149     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja13.10448     Document Type: Article

References (16)

1. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2012. Canberra: AIHW, 2012. (AIHW Cat. No. CAN 70; Cancer Series No. 74.) http://www.aihw.gov.au/ publication-detail/?id=60129542359 (accessed Nov 2013).
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
5. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
6. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011; 29: 489-498.
7. Di Giacomo AM, Danielli R, Calabrò L, et al. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunol Immunother 2011; 60: 467-477.
8. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
9. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010; 116: 1767-1775.
10. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
11. Therapeutic Goods Administration. Australian Public Assessment Report for ipilimumab. August 2011. http://www.tga.gov.au/pdf/ auspar/auspar-yervoy.pdf (accessed Oct 2013).
12. Pharmaceutical Benefits Advisory Committee. Ipilimumab (Yervoy). Public summary document. March 2012. http://www.pbs.gov. au/industry/listing/elements/pbac-meetings/ psd/2012-03/ipilimumab.pdf (accessed Oct 2013).
13. US Department of Health and Human Services National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events. Version 4.0. May 2009. http:// www.acrin.org/Portals/0/Administration/ Regulatory/CTCAE_4.02_2009-09-15_ QuickReference_5x7.pdf (accessed Oct 2013).
14. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progressionfree and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
15. Robert C, Schadendorf D, Messina M, et al; MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013; 19: 2232-2239.
16. Menzies AM, Haydu LE, Visintin L, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012; 18: 3242-3249.